The ability of the adult heart to generate new myocytes after injury is not established. Objective: Our purpose was to determine whether the adult heart has the capacity to generate new myocytes after injury, and to gain insight into their source.
A dult cardiac myocytes are terminally differentiated and are not thought to be capable of reentering the cell cycle and dividing. 1 Therefore, the adult heart has been viewed as a terminally differentiated organ, with no capacity for myocyte renewal with aging. 2 However, recent studies have suggested that new myocyte formation can occur in the adult heart with normal aging 3, 4 and in response to pathological stress. [5] [6] [7] These new myocytes appear to be derived from a cardiac myocyte precursor (progenitor) cell that resides within the myocardium. 8, 9 One type of cardiac precursor cell can be identified by the surface expression of the cKit receptor and the absence of the hematopoietic marker CD45. 8 These cKitϩ/CD45Ϫ cells have been shown 8 to have cardiogenic potential, both in vitro and in vivo. There are numerous varieties of putative cardiac precursor cells, 10 -12 but their roles in the normal physiology of the heart, or their ability and capacity for cardiac repair after injury is still not well known, especially in large animals and humans. 4 This topic is clearly of clinical relevance because human heart disease that culminates in cardiac performance deficits is largely the result of the loss of contractile cardiocytes, such as after a myocardial infarction. 13, 14 One reason why the adult heart is not thought to be capable of generating new myocytes is that it does not have the capacity to repair itself and recover normal structure and function after an injury that reduces myocyte number, such as a myocardial infarction. 7, 13, 14 Myocardial infarction-induced myocyte death produces pump function defects that require persistent activation of neurohumoral reflex systems to maintain systemic blood pressure. [15] [16] [17] Often the dysfunctional state degenerates into a syndrome called congestive heart failure, a leading cause of death in the United States.
The fact that myocyte loss is fundamentally related to the induction and progression of congestive heart failure has led to animal studies to test putative cardiac precursor cells for their ability to improve cardiac function. 8, 11, 18, 19 The success of some of these animal studies led to a number of clinical trials that have had mixed results. 20 At present, the mechanism for the modest improvement in cardiac performance shown in human cell therapy trials is unclear. Possibilities include the generation of new, fully functional myocytes that differentiate from the injected stem cells and integrate with the parent myocardium 21, 22 and improved survival or performance of the myocardium through a paracrine effect mediated by the injected cells. 23, 24 Another possibility is that the injected cells activate resident progenitor cells that are then responsible for enhanced endogenous cardiac repair. 24 -26 However, little is known about the ability of the adult mammalian heart to repair itself after injury.
The present study examined the idea that the adult heart of a large mammal has the ability to repair itself after injury by generating new cardiac myocytes. Injury was induced by infusion of isoproterenol (ISO) for 10 days. ISO caused diffuse myocardial injury throughout the heart, allowing comparison of endogenous repair in the atria and the ventricle. We infused 5-bromodeoxyuridine (BrdU) at various times during injury and recovery to identify proliferative cells. Our results show that during ISO injury, cKitϩ/CD45Ϫ cells in the atria and ventricles proliferate but few new myocytes form. During recovery from ISO injury, BrdUϩ myocyte nuclei were observed, and these myocytes appear to have been derived from resident cardiac precursors that were activated during the injury phase.
Methods

Isoproterenol (Catecholamine)-Induced Cardiomyopathy
Isoproterenol-induced cardiomyopathy was produced in adult felines at 5 to 6 months of age. These animals were divided into 3 groups and euthanized at day 10 (injury), day 17 (early recovery), or day 38 (late recovery) following ISO-filled minipump implantation at baseline (day 0) and removal at day 10. Full details can be found in the Methods section of the Online Data Supplement at http://circres.ahajournals.org.
Other Techniques
All other techniques used in this study have been described in previous studies, and details can be found in the Methods section of the Online Data Supplement.
Results
Chronic ISO Infusion Causes Depressed Systolic and Diastolic Function and Chamber Dilation
Catecholamines increase Ca 2ϩ influx and the contractility of cardiac myocytes, but if catecholamine exposure is persistent and excessive, it can induce myocyte apoptosis and necrosis, cardiac hypertrophy, replacement fibrosis, depressed cardiac pump function, and premature death. [27] [28] [29] In the present study, we developed an ISO-induced cardiac injury model in the feline heart so that we could explore the role of new myocyte formation in endogenous cardiac repair in an animal model with human-type physiological properties.
Cardiac structure and function were measured with echocardiography (ECHO) during and after 10 days of ISO injury. BrdU incorporation into proliferating cells was also measured to determine whether either injury or recovery from injury involved an endogenous cardiac repair process with the generation of new cardiac myocytes. Online Figure I details the experimental protocol for induction of ISO injury, the 7-day periods when BrdU-containing minipumps were inserted, and the timing of terminal studies.
Cardiac structure and function were measured with ECHO at baseline, during injury (day 7), at the end of the injury phase (day 10), during early recovery (day 17), and during late recovery (day 38) ( Figure 1 ). ISO initially enhanced cardiac function (not shown) but caused significant depression of left ventricular ejection fraction by day 7 (65.1Ϯ2.8, PϽ0.001) and day 10 (59.1Ϯ2.1, PϽ0.001) in comparison with control (74.2Ϯ1.1), with similar changes in fractional shortening ( Figure 1B and 1C ). There were also significant changes in the transmitral E/A ratio, suggesting the presence of abnormal diastolic function. These results are consistent with previous studies showing that chronic ISO treatment leads to reduced cardiac function and cardiac hypertrophy. 30 -32 The dose of ISO used in our study caused significant myocyte injury, as evidenced by increases in Troponin I (a cardiac contractile protein) in the blood (Online Figure II) . Troponin I levels peaked at 3 days and rapidly returned to control levels after removal of ISO minipumps. The increase in circulating myocyte contractile proteins suggests that ISO injury involves necrotic myocyte death.
ISO injury caused significant dilation of the left ventricle and atrium ( Figure 2 ). After removal of ISO-containing minipumps there was only modest recovery of systolic and diastolic function over the next 4 weeks (Figure 1 ). Atrial and ventricular chamber volumes showed some recovery toward control levels after the removal of ISO minipumps ( Figure 2 ). These results show that continuous ISO infusion for 10 days results in depressed systolic and diastolic function, myocyte injury, and chamber enlargement. On removal of ISO the heart appears to have some capacity for endogenous structural and functional repair.
ISO-Induced Cardiac Injury Is Associated With Cardiac and Myocyte Hypertrophy
Control and ISO-injured hearts were studied at the end of the injury phase, day 10, and during recovery phases at days 17 Figure 3 ). Hearts were weighed and then perfusion fixed for histological analyses (see below). Gross heart weight was normalized by tibia length ( Figure 3A ) and pre-ISO body weight ( Figure 3B ). The heart weight to tibia length ratio was increased at day 10 (1.52Ϯ0.09), and significantly increased at day 17 (1.54Ϯ0.07, PϽ0.05) and day 38 (1.49Ϯ0.05, PϽ0.05) in comparison with agematched control hearts (1.3Ϯ0.05) ( Figure 3A ). The heart weight to body weight ratio was also significantly increased at day 10 ( 
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Chronic ISO Exposure Induces Replacement Fibrosis
The collagen content (and overall tissue structure) of control and ISO-injured hearts was determined in tissue sections ( Figure 4 and Online Figure IV ). The collagen content was increased in all regions of the heart (Figure 4A and 4B) and there were small areas of focal injury with replacement fibrosis (Online Figure IV) . The collagen staining in the left ventricle was significantly increased at day 10 (13.19%Ϯ 1.74%, PϽ0.001), day 17 (11.33%Ϯ1.59%, PϽ0.001), and day 38 (11.02%Ϯ0.94%, PϽ0.001) when compared with control tissue (3.46%Ϯ0.61%) ( Figure 4C ). Similar amounts of replacement fibrosis were found for the right ventricle and left and right atria ( Figure 4D through 4F).
ISO Injury Causes Depressed Myocyte Contractility
Myocytes were studied at the end of the injury phase (day 10) to determine whether depressed global cardiac function was associated with reduction in the density and ISO responsiveness of the L-type Ca 2ϩ current and depression of myocyte contraction and systolic Ca 2ϩ transients. L-type Ca 2ϩ current was significantly smaller than control in myocytes from ISO-injured hearts and showed almost no response to bath application of ISO (Online Figure Figure VF through VH) were significantly smaller in myocytes from ISO-injured hearts than in myocytes from controls, and these myocytes had blunted responses to applied catecholamines. These changes in myocyte contractility and Ca 2ϩ handling are similar to those we have found previously in feline models of pressure overload-induced cardiac dysfunction 33 and in failing human ventricular myocytes. 34, 35 These results show that our ISO-induced cardiac injury model causes alterations in myocyte Ca 2ϩ handling reminiscent of those found in other forms of cardiac disease.
BrdU؉ Myocyte Nuclei Increase in Left Atrium, but Only After Removal of ISO Minipumps
Histological analysis of left atrial tissue was performed at the end of the injury phase (day 10) and during spontaneous recovery at days 17 and 38. BrdU was infused for 7 days before euthanasia, except in one group of animals for which it was infused during the injury phase (pulse), and then animals were euthanized at day 38 (chase) (Online Figure I) . 
Day 10: End of Injury Phase
A small percentage of nonmyocyte nuclei were BrdUϩ, and very few myocyte nuclei were BrdUϩ in uninjured control tissues ( Figure 5A , 5D, and 5E). ISO-induced injury was associated with significant increases in total BrdUϩ nuclei at day 10 (17.03%Ϯ2.74%, PϽ0.001) in comparison with control (1.51%Ϯ0.37%). BrdUϩ nuclei were abundant (Figure 5B, 5D, and 5E), and almost all of these labeled cells were nonmyocytes. There was no significant increase in BrdUϩ myocyte nuclei in the left atrium (LA) during the ISO injury phase, and the percentage of BrdUϩ myocyte nuclei was very low (0.0177%Ϯ0.0129% in comparison with 0.0187%Ϯ 0.0089% in controls). These studies show that ISO injury causes an increase in the number of proliferative nonmyocytes in the left atrium, with no detectable increase in the number of newly formed atrial myocytes, at least as defined by BrdU incorporation.
Day 17: 7 Days After Removal of ISO Minipumps
At day 17 (BrdU infused from day 10 to day 17) there was a significant decrease in the number of total BrdUϩ nuclei (3.13%Ϯ0.75%) versus that observed at day 10, and the total number of BrdUϩ nuclei had returned to almost control levels ( Figure 5C and 5D ). However, there was a significant (80-fold) increase in the number of BrdUϩ LA myocyte nuclei (1.53%Ϯ0.73%, PϽ0.05), and BrdUϩ myocyte nuclei were easily identified in every tissue section ( Figure 5C ). These results show that after removal of ISO the proliferation of most nonmyocytes in the left atria decreased rapidly while the number of BrdUϩ myocytes increased. This increase in BrdUϩ myocytes was associated with improved cardiac performance (see above).
Day 38: 28 Days After Removal of ISO Minipumps
Animals euthanized at day 38 had BrdU minipumps inserted either during cardiac injury (pulse-chase studies) or for 7 days prior to euthanasia ( Figure 5E ). ISO-injured animals that received BrdU minipumps 1 week prior to euthanasia at day 38 did not have increased numbers of BrdUϩ myocyte and nonmyocyte nuclei than did controls. These results suggest that by day 38 any endogenous cardiac repair that does not involve nonmyocyte or myocyte proliferation had been largely completed.
In animals in which BrdU minipumps were implanted during the ISO injury phase (pulse), the number of total BrdUϩ LA nuclei (10.70%Ϯ2.44%, PϽ0.001) and BrdUϩ LA myocyte nuclei (2.045%Ϯ0.746%, PϽ0.01) at day 38 (chase) were significantly greater than in controls. These results show that nonmyocytes that proliferated during the ISO injury phase were still present in the heart after repair was completed. Our results with BrdU infusion during the ISO injury phase and heart explant at day 10 (above) showed that only nonmyocytes are proliferative at this time. Here, we show that identical BrdU infusion during injury (and then pumps are removed) resulted in a significant increase in the number of BrdUϩ atrial myocytes at day 38, suggesting that these BrdUϩ myocytes were derived from BrdUϩ nonmyocytes that were labeled during the injury phase.
BrdU؉ Myocyte Nuclei Also Increase in Left Ventricle, but Again, Only After Removal of ISO Minipumps
Histological evaluation of left ventricular tissue ( Figure 6 ) was performed as described above for left atrial samples.
Day 10: End of Injury Phase
In control left ventricle (LV) samples, a small percentage of the nuclei were BrdUϩ, and almost all of these nuclei were in nonmyocytes. BrdUϩ myocyte nuclei were rarely observed in control hearts of animals of this age ( Figure 6C and 6D ).
As we observed in the study of atrial tissue, ISO injury was associated with significant increases in total BrdUϩ nuclei at day 10 (18.6%Ϯ2.9%, PϽ0.001) in comparison with control (2.5%Ϯ0.4%) LV tissue. The increase was almost exclusively in nonmyocytes. There was no detectable increase in BrdUϩ myocyte nuclei in the LV following ISO treatment (0.0066%Ϯ0.0034%) in comparison with controls (0.0066%Ϯ 0.0038%).
Day 17: 7 Days After Removal of ISO Minipumps
At day 17 (BrdU infused from day 10 to day 17) there was a significant decrease in the number of total BrdUϩ nuclei (4.67%Ϯ0.63%) in comparison with that observed at day 10. The percentage of BrdUϩ nuclei was slightly greater than that observed in control hearts. However, we found a significant (10-fold) increase in the number of BrdUϩ LV myocyte nuclei (0.08%Ϯ0.028%, PϽ0.05) ( Figure 6A and 6B and Online Figure VI) . However, the percentage of BrdUϩ LV myocyte nuclei was more than 10-fold lower than what we observed in the atria (see above). These results show that there is no detectable new myocyte formation during the ISO injury phase, but there is a significant increase in the number of proliferative, small, nonmyocytes during this time period. After removal of ISO the proliferation of nonmyocytes decreases toward control levels but the number of BrdUϩ myocytes increase, consistent with new myocyte formation in association with improved ventricular performance.
Day 38: 28 Days After Removal of ISO Minipumps
ISO-injured animals that received BrdU minipumps 1 week prior to euthanasia at day 38 had the same percentage of BrdUϩ myocyte and nonmyocyte nuclei that were observed in control tissues ( Figure 6C and 6D) . These results are consistent with our observations in the atria and show that aspects of cardiac repair after ISO injury that involved enhanced proliferation of cells within the myocardium have returned to control levels within weeks after injury.
In animals with BrdU minipumps implanted during the ISO injury phase and then removed, the number of total BrdUϩ nuclei (9.35%Ϯ3.04%, PϽ0.05) and BrdUϩ myocyte nuclei (0.04%Ϯ0.01%, PϽ0.01) at day 38 were significantly greater than in controls ( Figure 6C and 6D) . These results show that many of the BrdU-labeled nonmyocyte nuclei are still present after repair of ISO-induced injury. More important, these data suggest that the BrdUϩ myocytes found at day 38 were derived from BrdUϩ cardiac precursors that were BrdU labeled during the injury phase. Our collective results show that the adult feline heart has some capacity to generate new myocytes after injury. We also show that significantly more brightly stained BrdUϩ myocytes are found in the atria than in the ventricle after ISO-induced injury.
"Dimly" BrdU؉ Myocytes in Pulse-Chase Experiments
Our pulse-chase studies show that infusion of BrdU during ISO injury labeled nonmyocytes, which appear to differentiate into new myocytes after removal of ISO (and BrdU) at day 10. If these newly formed myocytes are transiently proliferative, then in these pulse-chase studies we would expect to see myocytes containing low levels (dimly labeled) of BrdU, because the label would be diluted with each cell division. All the results reported above were from analysis of "brightly" labeled cells. An analysis of "dimly" labeled cells was performed in LV samples from 3 hearts from each of our time points (day 10, day 17, day 38, and day 38 pulse-chase). No significant numbers of "dimly" BrdUϩ nuclei were found in any of the hearts in which BrdU was infused for 7 days prior to sacrifice. Only "brightly" labeled myocytes and nonmyocytes were observed. However, a significant number (12.6%Ϯ6.3%) of LV myocytes had low levels of BrdU labeling (Online Figure VII) in the pulse-chase group. Similar results were found in the left atria (data not shown). These results are consistent with the idea that some of the new myocytes derived from BrdUϩ nonmyocyte precursor cells proliferate transiently before exiting the cell cycle.
cKit؉ and CD45؉ Cells in Heart Proliferate With Cardiac Injury
Our most provocative finding is that we detected BrdUϩ myocytes in the atria and ventricle, weeks after BrdU labeling of nonmyocytes during the injury phase. The nature and source of these proliferative cells is not clear. They could be derived from cells that normally reside within the heart, 8, 9, 36 or from cells that enter the heart from the blood during injury. 6, 10, 19, 37 Although a variety of precursor cells with the ability to form new cardiovascular tissue have been identified, 8, 11, 38 we studied those cardiac progenitor cells expressing the stem cell receptor cKit (CD117) that did not express markers of the hematopoietic lineage (cKitϩ/CD45Ϫ). 8 We also studied hematopoietic cells 39 that expressed both cKit and CD45 (leukocyte common antigen) (cKitϩ/CD45ϩ). 6, 40 We analyzed cardiac tissue sections from control, injury (day 10), early (day 17), and late recovery (day 38) for cKit, CD45, and BrdU incorporation to determine whether cKitϩ or CD45ϩ cells were proliferative during ISO injury.
In the left ventricle and the left atrium, cKit cells ( Figure  7A ) were a minor fraction of the total cell population ( Figure  7B and 7E ). There was a small increase in the percentage of cKitϩ cells in the LV at day 10, but this difference failed to reach statistical significance. In the left ventricle there was a significant increase (6-fold) in the percentage of cKitϩ cells that were BrdUϩ (0.0722%Ϯ0.01%, PϽ0.001) during the ISO injury period (day 10) in comparison with control (0.0115%Ϯ0.0027%) (Figure 7 and Online Figure VIII) .
The percentage of CD45ϩ cells in the heart was also very small and did not change at any of the time periods that we examined. There was a smaller (than cKit cells) increase (2-fold) in the percentage of CD45ϩ/BrdUϩ nuclei at day 10 (0.0193%Ϯ0.0018%, PϽ0.01) in comparison with control (0.0081%Ϯ0.0018%) (Online Figures VIII through X) .
To determine whether cKitϩ or CD45ϩ cells in the left ventricle were more proliferative during the injury phase, we calculated the ratio of cKitϩ/BrdUϩ (or CD45ϩ/BrdUϩ) to cKitϩ (or CD45) nuclei. There was a significant increase (5-fold) in the ratio of cKitϩ/BrdUϩ to cKitϩ nuclei at day 10 (0.369Ϯ0.048, PϽ0.001) in comparison with control (0.067Ϯ0.015) (Figure 7 and Online Figure VIII ). This was much larger than the increase (2-fold) in the ratio of CD45ϩ/ BrdUϩ to CD45ϩ nuclei at day 10 (0.126Ϯ0.014, PϽ0.01) in comparison with control (0.064Ϯ0.009) (Online Figures  IX and X) . The percentage of cKitϩ/BrdUϩ cells was not different from control at days 17 and 38 (with BrdU infused 7 days before euthanasia). Similar results were observed for CD45ϩ cells. These results show that although both cKitϩ and CD45ϩ cells in the heart are proliferative during the injury phase, their absolute number does not increase dramatically during either the injury or repair period. In the left atrium ( Figure 7E through 7G) , ISO injury was associated with a significant increase (14-fold) in the percentage of cKitϩ/BrdUϩ nuclei at day 10 (0.0767%Ϯ0.0171%, PϽ0.01) in comparison with control (0.0052%Ϯ0.0034%) (Figure 7) . The percentage of CD45ϩ/BrdUϩ nuclei was somewhat increased at day 10 (0.022%Ϯ0.0065%; PϽ0.07) in comparison with control (0.0068%Ϯ0.0039%) (Online Figures IX and X) . We also analyzed the ratio of cKitϩ/ BrdUϩ to cKitϩ nuclei in the left atrium. There was a significant increase (10-fold) in the ratio of c-kitϩ/BrdUϩ to cKitϩ nuclei at day 10 (0.384Ϯ0.086, PϽ0.01) in comparison with control (0.038Ϯ0.026). Similar to the left ventricle, this was a much larger increase than that seen for the increase (3-fold) in the ratio of CD45ϩ/BrdUϩ to CD45ϩ nuclei at day 10 (0.130Ϯ0.031, PϽ0.05) in comparison with control (0.043Ϯ0.024), indicating a more active proliferative response by cKitϩ progenitor cells following injury. These data show that the cKitϩ (Figure 7) and CD45ϩ (Online Figure  IX) cell populations in the atria and ventricle proliferate following ISO injury and that the magnitude of the proliferative response is greater in the atria.
In animals in which BrdU minipumps were implanted during the ISO injury phase and then removed at day 10, with hearts explanted at day 38, the percentage of cKitϩ/BrdUϩ left atrial nuclei (0.0426%Ϯ0.0063%, PϽ0.001) and the ratio of cKitϩ/BrdUϩ to cKitϩ nuclei (0.162Ϯ0.022, PϽ0.05) was significantly greater than that in controls (Figure 8 ). In comparison, ISO-injured animals that received BrdU minipumps 1 week prior to sacrifice at day 38 did not have an increased percentage of cKitϩ/BrdUϩ left atrial nuclei or an increased ratio of cKitϩ/BrdUϩ to cKitϩ nuclei. These results suggest that a small group of the proliferative cKitϩ/ BrdUϩ cells that were labeled during the injury phase were still present at day 38. Although a similar trend was seen in the left ventricle, these changes were not significant, again indicating a somewhat less robust regenerative response in the left ventricle than in the left atrium.
cKit؉ Cells Are Both CD45؉ and CD45؊
Resident cardiac progenitor cells are thought to be cKitϩ/ CD45Ϫ, 8 whereas cKitϩ cells from the bone marrow are thought to be CD45ϩ. 40 We showed above that BrdU incorporation into cKitϩ cells following injury was much greater than in CD45ϩ cells, suggesting that most of the cKitϩ cells we stained were not of hematopoietic origin. To further address this issue, we costained tissue sections for cKit and CD45 (Figure 8 ). The relative percentages of cKitϩ/CD45Ϫ (called cKit), cKitϪ/CD45ϩ (called CD45), and cKitϩ/CD45ϩ cells were measured. All 3 varieties of cells were observed in both the left atrium and ventricle (Figure 8 There was no significant change (with a trend toward a decrease) in the number of both CD45ϩ and cKitϩ/CD45ϩ cells during the injury (day 10) and early recovery phases (day 17). These data show that ISO injury selectively increased proliferation of small nonmyocytes that are cKitϩ/ CD45Ϫ, at a time when we saw little evidence for new myocyte formation. Our overall findings are consistent with the idea that ISO injury induces the proliferation of a cKitϩ/CD45Ϫ resident cardiac precursor cell that expands the progenitor cell pool and could be the source of the new cardiac myocytes that we observed during the recovery phase.
Our data also suggest that this response is more robust in the atria than in the ventricle.
Discussion
Cardiac dysfunction resulting from the death of cardiac myocytes is a major health problem and a leading cause of heart failure. 41 Many previous studies have documented that the adult cardiac myocyte is terminally differentiated with no apparent ability to reenter the cell cycle and divide. 1,2 Therefore, pathological insults that reduce myocyte number decrease contractile mass and increase the contractile stress on surviving myocytes. Because adult myocytes cannot divide, the principle mechanism for restoring contractile mass in the face of pathological stress is thought to be myocyte hypertrophy rather than myocyte regeneration. 2, 4, 14 However, recent findings support the idea that the adult heart contains a population of resident progenitor cells with some capacity for new myocyte generation. 4, 7, 8 Animal studies in which these putative cardiac precursor cells are injected into the damaged heart have shown enhanced cardiac function. 8, 18 These findings have fueled a number of clinical trials that test the ability of different adult stem cells to restore cardiac function in patients with damaged hearts. 20 It is difficult to interpret these clinical studies with our limited understanding of the capacity of the adult heart to generate new myocytes in normal or pathological states. Our study suggests that cardiac myocyte regeneration can take place in the adult hearts of large mammals with injury caused by ISO infusion and that resident cardiac precursor cells might be the source of these new myocytes. Our experiments showed that ISO infusion caused cardiac injury with depressed systolic and diastolic function (Figure 1) , dilation of the atria and ventricles (Figure 2 ), cardiac and myocyte hypertrophy (Figure 3 ), and replacement fibrosis (Figure 4) . There was some improvement in these parameters after ISO removal, consistent with endogenous repair. These results suggest that ISO caused necrotic myocyte loss, 42 with reactive fibrosis and hypertrophy. 27 Myocytes studied at the end of the injury phase had many of the features of those in end-stage failing human hearts, [33] [34] [35] including reduced L-type Ca 2ϩ channel currents with reduced ISO responsiveness, depressed myocyte contractions and Ca 2ϩ transients, and blunted ISO responsiveness (Online Figure V) . These results show that ISO causes diffuse cardiac injury and results in cardiac structural and functional remodeling, with substantial reactive myocyte hypertrophy. The major purpose of our study was to determine whether the cardiac repair that follows this type of injury includes any myocyte regeneration.
ISO Injury Activates a Cardiac Precursor Pool
Our experiments showed that during ISO injury there was a large increase in the number of proliferative (defined by BrdU incorporation) cells in the atria and ventricle. We were surprised that almost 20% of all atrial and ventricular nuclei were BrdUϩ at the end of the ISO injury period (Figures 5  and 6 ). A major finding was that few BrdUϩ myocyte nuclei were identified during this time period. This lack of BrdUϩ myocyte nuclei during ISO injury reduced concern that BrdU was incorporating into myocytes needing to repair their DNA, which would have caused a significant increase in BrdUϩ myocyte nuclei at the end of the injury phase (day 10). This proliferative phase was clearly associated with ISO injury, because when BrdU was infused after removal of ISO, the rate of BrdU incorporation immediately decreased to levels close to those in normal hearts. We did not define the identity of all BrdUϩ cells in the injured heart, but did examine the cKitϩ/CD45Ϫ cells thought to be resident cardiac precursors 8 as well as the cKitϩ/CD45ϩ cells that are thought to be derived from the bone marrow via the blood stream. 11, 18 The relative abundance of CD45ϩ cells did not increase substantially during injury, but both cKitϩ and CD45ϩ cells were proliferative during ISO injury (Figure 7 and Online Figures  IX and X) . The putative resident cardiac precursor cells (cKitϩ/CD45Ϫ) were the only cells that increased in relative abundance during ISO injury (Figure 8 ), and they were more proliferative than cKitϩ/CD45ϩ during the injury phase. These results show that ISO injury leads to proliferation of a pool of cells that are thought to have cardiogenic potential, 8 but no increase in new cardiac myocyte formation (defined by us as BrdUϩ myocytes) was observed during this time period. These results are reminiscent of our observations in failing human hearts 6 where we found an increase in cKitϩ cells that were not repairing the damaged heart.
Cardiac Repair Includes New Myocyte Formation
Histological studies of cardiac tissue from hearts recovering from ISO injury clearly identified BrdUϩ myocyte nuclei, but only under specific BrdU-labeling conditions. Significant numbers of BrdUϩ myocyte nuclei were found at day 17 (7 days of recovery, with BrdU infused from days 10 to 17). Importantly, BrdUϩ nonmyocyte labeling was only slightly greater than control, and significantly less than during injury with this labeling strategy. Significant numbers of BrdUϩ myocyte nuclei were also found after 4 weeks (day 38) of recovery, but only in animals in which BrdU was infused during injury ( Figures 5 and 6) . The pulse-chase procedure also produced a significant number of dimly BrdU-labeled cardiac myocytes, consistent with the idea that some of the new myocytes derived from BrdU-labeled precursor cells were transiently proliferative. This putative proliferation would have had to be complete by our day 31, because BrdU infusion from days 31 to 38 failed to label a significant number of cardiac myocytes.
Are New Cardiac Myocytes Derived From a cKit؉/CD45؊ Precursor Pool?
Our results support the hypothesis that ISO injury induces proliferation of resident cardiac (cKitϩ/CD45Ϫ) progenitors, but these cells do not differentiate into new cardiac myocytes during injury (Online Figure XI) . On removal of ISO, these activated (BrdUϩ) cardiac precursors appear to differentiate into new cardiac myocytes. Our results suggest that new myocyte formation during recovery required a proliferative step, because myocyte BrdU labeling during days 10 to 17 yielded a similar number of brightly labeled BrdUϩ myocytes as observed at day 38, when BrdU was infused during ISO injury. BrdU infusion during days 10 to 17 did not increase the BrdU labeling of the cKitϩ/CD45Ϫ pool (Figure 7 ), suggesting that cKitϩ precursor cells were not proliferative at this time. Therefore, the simplest explanation of our composite results is that new myocytes are generated from a partially committed (to the cardiac lineage) cKitϩ precursor cell that was activated (and proliferative) during the ISO-injury phase. During the recovery period these precursor cells appear to commit to the cardiac lineage to form "new" cardiac myocytes. At least some of these new myocytes proliferated one or more times to become brightly BrdUϩ when BrdU was infused from day 10 to 17. Some of the newly formed myocytes derived from BrdUϩ cardiac precursors appear to be transiently proliferative (between days 10 and 38), producing a population of "dimly" BrdUϩ myocytes in our pulse-chase protocol. Only by varying the timing of BrdU infusion during injury and recovery could we reach these conclusions (Online Figure XI) .
Is There More Regeneration in the Atria Than the Ventricle?
Our results suggest that myocyte regeneration (as defined by BrdUϩ myocytes) is more robust in the atria than in the ventricle. The reasons for these differences are not clear and deserve additional study. Studies by others 43 have shown a greater abundance of and organized (into niches) environment for cKitϩ cardiac precursor cells in the atria than in the ventricle. If atrial tissue is a better source of cardiac precursors with greater regenerative potential, then our findings suggest that cardiac precursors isolated and expanded from the atria might be a better source of cells for autologous cardiac cell therapy. Our study also suggests that the newly formed myocytes are transiently proliferative and this lowers their BrdU content, reducing the ability to detect BrdU in the myocyte nucleus if short-term BrdU labeling is used. More reliable approaches for identifying new myocytes and tracing their lineage would help future studies.
Limitations
This study was performed with an ISO injury model rather than with a myocardial infarction model for a number of reasons. Substantial infarcts are not easily obtained in felines because of robust collateral circulation. We recognize that ISO injury has limitations, but it produces a reliable, reproducible, diffuse injury that can be rapidly terminated by removal of ISO minipumps. Therefore, it allowed us to have a defined injury phase and a rapid removal of the noxious stimulus. These characteristics turned out to be significant advantages in the present study.
We are cautious when BrdU is used to identify "new" myocytes because it could also be incorporated into myocyte DNA during repair or in myocytes with DNA synthesis without cytokinesis. Our composite findings are not consistent with these possibilities. We did not see any significant increases in BrdU incorporation (bright or dim) into myocytes during injury; we only observed brightly BrdUϩ myocytes when we labeled during days 10 to 17 or in pulse-chase studies. The only time we observed dimly BrdUϩ myocytes was in our pulse-chase studies, when BrdU was not infused during the times when BrdUϩ myocytes were observed. These observations are most consistent with the conclusions stated. However, we cannot entirely rule out the caveats raised above.
In summary, our data show that the adult heart has the ability to generate new myocytes after injury. The contribution of new myocytes to improved function of the ventricle cannot be determined with our approaches, and we may have underestimated the number of new myocytes with the intermittent BrdU-labeling strategy used. Our composite results are most consistent with the hypothesis that ISO injury caused proliferation and activation of the cKitϩ cardiac myocyte precursor pool and that these cells differentiated into new cardiac myocytes that proliferate at least 1 time before they exit the cell cycle. Our results also suggest that there appears to be something about the environment of the ISO-injured heart that blunts the differentiation of cardiac precursors into functional new myocytes. If these factors could be identified and eliminated, then endogenous cardiac repair might be enhanced.
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